Anticipate generic drug launch
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Find generic entry opportunities
Manage your formulary budget
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Continuous administration adenosine to increase myocardial blood flow|
|Abstract:||This invention is concerned with the use of adenosine as an agent for the treatment of human beings. More particularly, this invention is concerned with the administration of adenosine to human patients by continuous intravenous infusion for, inter alia, control of blood pressure, use as a selective vasodilator, decreasing pulmonary vascular resistance, treating acute pulmonary hypertension in conjunction with idiopathic respiratory distress syndrome, in diagnosing pulmonary hypertension in conjunction with cardiac septum defects, in percutaneous transluminal angioplasty (PTCA), in coronary thrombolysis (CTL) and in radionucleide scintography.|
|Inventor(s):||Sollevi; Alf (Bromma, SE)|
|Assignee:||Item Development Aktiebolag (Stocksund, SE)|
|Filing Date:||Jan 14, 1992|
|Claims:||1. A method of dilating the coronary arteries of a human patient in need thereof without inducing a hypotensive state, which comprises administering adenosine into the blood stream of the patient by continuous intravenous infusion at a rate effective to dilate the coronary arteries, while causing systemic arteries to dilate substantially less than the coronary arteries, such rate being from about 30 to 50 .mu.g per kg of body weight per minute when administered in a central vein. |
2. A method according to claim 1 wherein the occlusion of coronary grafts in a human patient who has undergone coronary bypass surgery is inhibited by increasing graft blood flow without increased myocardial work comprising administering adenosine to the blood stream of the patent by continuous intravenous infusion.
3. A method according to claim 2 comprising administering adenosine at a rate of 0.03 mg to 0.05 mg per kg body weight per minute so as to increase graft flow and obtain preferential vasodilation in the coronary vasculature.
4. A method of dilating the coronary arteries of an anesthetized human patient in need thereof during coronary bypass surgery which comprises administering adenosine into the blood stream of the patient by continuous intravenous infusion so as to cause a preferential coronary vasodilation, the adenosine being administered at dosages from about 30 to 50 .mu.g per kg per minute when administered in a central vein.
5. A method according to claim 1 where the patient is not anesthetized.
6. A method according to claim 1 where the patient is anesthetized.
7. A method of increasing the myocardial blood flow in a human patient in need thereof which comprises administering adenosine into the blood stream of the patient by continuous intravenous infusion at a rate effective to dilate the coronary arteries, such rate being from about 50 to about 100 .mu.g per kg body weight per minute when administered in a central vein.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.